Rhumbline Advisers trimmed its position in USANA Health Sciences, Inc. (NYSE:USNA) by 15.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,082 shares of the company’s stock after selling 1,973 shares during the period. Rhumbline Advisers’ holdings in USANA Health Sciences were worth $821,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. US Bancorp DE grew its position in USANA Health Sciences by 730.1% in the 4th quarter. US Bancorp DE now owns 2,374 shares of the company’s stock valued at $176,000 after buying an additional 2,088 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in USANA Health Sciences in the 3rd quarter valued at $189,000. Creative Planning purchased a new position in USANA Health Sciences in the 4th quarter valued at $219,000. Hikari Power Ltd purchased a new position in USANA Health Sciences in the 4th quarter valued at $255,000. Finally, Ifrah Financial Services Inc. acquired a new stake in USANA Health Sciences in the fourth quarter valued at $278,000. Hedge funds and other institutional investors own 48.23% of the company’s stock.
A number of equities research analysts have commented on the company. Pivotal Research raised their target price on USANA Health Sciences from $80.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. TheStreet downgraded USANA Health Sciences from a “b+” rating to a “c+” rating in a report on Tuesday, February 6th. Finally, Sidoti downgraded USANA Health Sciences from a “buy” rating to a “neutral” rating in a report on Wednesday, January 24th.
USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 6th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.11. USANA Health Sciences had a return on equity of 27.08% and a net margin of 5.97%. The company had revenue of $273.11 million during the quarter, compared to the consensus estimate of $258.67 million. During the same quarter last year, the company earned $0.87 earnings per share. USANA Health Sciences’s quarterly revenue was up 8.0% compared to the same quarter last year. equities research analysts expect that USANA Health Sciences, Inc. will post 4.25 EPS for the current year.
In other news, major shareholder Global Ltd Gull sold 82,407 shares of USANA Health Sciences stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $81.24, for a total transaction of $6,694,744.68. Following the completion of the transaction, the insider now owns 11,439,646 shares of the company’s stock, valued at approximately $929,356,841.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Myron W. Wentz sold 78,129 shares of USANA Health Sciences stock in a transaction on Friday, March 9th. The stock was sold at an average price of $81.19, for a total value of $6,343,293.51. The disclosure for this sale can be found here. In the last three months, insiders sold 689,767 shares of company stock valued at $54,575,633. 53.20% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.wkrb13.com/2018/04/01/rhumbline-advisers-has-821000-position-in-usana-health-sciences-inc-usna.html.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.